10.91USD-2.50%Mkt Cap: 220.67M USDP/E: —Last update: 2026-05-26
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-be…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap220.67M USD
Enterprise Value-43.12M USD
Revenue (TTM)33.18M USD
Gross Profit-61.35M USD
Net Income (TTM)87.01M USD
Revenue/Share1.037 USD
Last Price10.91 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees87
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.80
PEG—
EV/EBITDA0.41
EV/Revenue-1.30
P/S6.69
P/B0.78
EPS (TTM)-2.53
EPS (Forward)-6.22
52W Range
9.7909% of range22.55
52W High22.55 USD
52W Low9.790 USD
Profitability
Gross Margin-184.89%
Oper. Margin-7050.95%
EBITDA Margin0.00%
Profit Margin35.65%
ROE28.70%
ROA25.74%
Growth
Revenue Growth-99.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF107.50M USD
CapEx (TTM)1.55M USD
FCF Margin-113.58%
FCF Yield-17.08%
Net Debt-265.19M USD
Net Debt/EBITDA2.51
Balance Sheet
Debt/Equity0.06
Current Ratio22.61
Quick Ratio22.17
Book Value/Sh14.47 USD
Cash/Share14.22 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.1 (Buy)
Target (Mean)21.83 USD
Target Range16.00 USD – 30.00 USD
# Analysts6
Ownership
Shares Out.19.79M
Float17.83M
Insiders3.65%
Institutions96.04%
Short Interest
Short Ratio4.1d
Short % Float8.23%
Short % Out.7.16%
Shares Short1.42M
Short (prev mo.)1.49M
Technical
SMA 5011.36 (-4.0%)
SMA 20015.35 (-28.9%)
Beta0.95
S&P 52W Chg28.31%
Avg Vol (30d)330.41K
Avg Vol (10d)435.86K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—